Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain's hidden rewiring revealed in glioma patients

NCT ID NCT07612917

Knowledge-focused Sponsor: Johannes Kepler University of Linz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study tracks how brain areas controlling movement, language, and sensation change during glioma treatment. Twenty patients with brain tumors will undergo repeated MRI scans as part of their regular care. Researchers aim to understand the brain's ability to adapt over time, which may guide future therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better understand how the brain rewires itself during glioma treatment, potentially improving future therapies.
What could go wrong
This is a small, early observational study with only 20 participants, so findings may not apply to all patients. It does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with diffuse gliomas (WHO grade 2-4) undergoing multimodal treatment and eligible for functional MRI and neurocognitive assessment.

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with diffuse gliomas (WHO grade 2-4). * Age \>18 years and \<65 years. * Written participant information and informed consent provided and signed. * Signed informed consent for functional magnetic resonance imaging (fMRI). Exclusion Criteria: * Age \<18 years or \>65 years. * Pregnancy. * Contraindications to MRI, including but not limited to: * Active medical implants (e.g., pain pump, defibrillator, cardiac pacemaker), * Orthodontic braces, * Metallic tattoos, * Non-removable piercings, * Known metallic foreign bodies, * Claustrophobia. * Cerebral metastases from secondary (non-primary) tumors. * Absence of baseline BOLD functional MRI and/or baseline neurocognitive assessment. * Failure to provide written participant information and informed consent. * Karnofsky Performance Status (KPS) \<60, unless feasibility of clinical-psychological testing and BOLD fMRI is confirmed by the investigator in consultation with clinical psychology, radiology staff, and the patient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fmri research are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain glioma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fmri research Glioma (any grade) in the brain Gliomas, malignant Neurocognitive function

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kepler University Hospital

    RECRUITING

    Linz, Upper Austria, 4020, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.